CL2022002094A1 - Célula cho que expresa heterodímeros il-15 - Google Patents

Célula cho que expresa heterodímeros il-15

Info

Publication number
CL2022002094A1
CL2022002094A1 CL2022002094A CL2022002094A CL2022002094A1 CL 2022002094 A1 CL2022002094 A1 CL 2022002094A1 CL 2022002094 A CL2022002094 A CL 2022002094A CL 2022002094 A CL2022002094 A CL 2022002094A CL 2022002094 A1 CL2022002094 A1 CL 2022002094A1
Authority
CL
Chile
Prior art keywords
cho cell
heterodimers
cell expressing
heterodimer
treatment
Prior art date
Application number
CL2022002094A
Other languages
English (en)
Inventor
Gabriel Richard
Jostock Thomas
JOZEFCZUK Justyna
Ulrich LOHRIG Urs
Aurélien Pons Alexandre
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2022002094A1 publication Critical patent/CL2022002094A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al heterodímero de IL-15/IL-15Ra producido en una línea celular CHO, y método de producción del heterodímero y método de tratamiento utilizando el heterodímero.
CL2022002094A 2020-02-05 2022-08-03 Célula cho que expresa heterodímeros il-15 CL2022002094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062970485P 2020-02-05 2020-02-05

Publications (1)

Publication Number Publication Date
CL2022002094A1 true CL2022002094A1 (es) 2023-03-10

Family

ID=74554194

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022002094A CL2022002094A1 (es) 2020-02-05 2022-08-03 Célula cho que expresa heterodímeros il-15
CL2023002447A CL2023002447A1 (es) 2020-02-05 2023-08-17 Célula cho que expresa heterodímeros il-15

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023002447A CL2023002447A1 (es) 2020-02-05 2023-08-17 Célula cho que expresa heterodímeros il-15

Country Status (21)

Country Link
US (1) US20210244821A1 (es)
EP (1) EP4100425A1 (es)
JP (2) JP2022522566A (es)
KR (1) KR20220137651A (es)
CN (1) CN115023436A (es)
AR (1) AR121261A1 (es)
AU (1) AU2021215893A1 (es)
BR (1) BR112022014493A2 (es)
CA (1) CA3168469A1 (es)
CL (2) CL2022002094A1 (es)
CO (1) CO2022010860A2 (es)
CR (1) CR20220367A (es)
DO (1) DOP2022000156A (es)
EC (1) ECSP22060286A (es)
IL (1) IL295278A (es)
JO (1) JOP20220174A1 (es)
MX (1) MX2022009611A (es)
PE (1) PE20221509A1 (es)
TW (1) TW202142558A (es)
UY (1) UY39062A (es)
WO (1) WO2021156720A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022090202A1 (en) 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15RBβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
IL302321A (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15RBY agonist for the treatment of squamous cell carcinoma
WO2024097918A1 (en) 2022-11-04 2024-05-10 Novartis Ag Nkg2d fusion protein cancer therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
PL1899364T3 (pl) 2005-05-17 2020-08-24 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
WO2007070488A2 (en) 2005-12-12 2007-06-21 The Cbr Institute For Biomedical Research, Inc. Integrin alpha l i domain mutants with increased binding affinity
JP5709356B2 (ja) 2006-01-13 2015-04-30 アメリカ合衆国 哺乳動物細胞における発現のためのコドン最適化ＩＬ−１５およびＩＬ−１５Ｒ−α遺伝子
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
CA3028038C (en) 2007-05-11 2021-08-10 Altor Bioscience Corporation Fusion molecules and il-15 variants
KR101577849B1 (ko) 2008-08-22 2015-12-15 마그나 시팅 인크. 감소된 백래쉬를 갖는 디스크 리클라이너
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
PT2619229T (pt) 2010-09-21 2016-07-13 Altor Bioscience Corp Moléculas de fusão de il-15 multiméricas solúveis e métodos de produção e utilização das mesmas
AU2013334610B2 (en) * 2012-10-24 2018-09-13 Novartis Ag IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes
AU2015254913B2 (en) 2014-04-29 2018-05-17 Novartis Ag Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
AU2015366795B2 (en) * 2014-12-19 2020-12-17 Jiangsu Hengrui Medicine Co., Ltd. Interleukin 15 protein complex and use thereof
US20190169253A1 (en) * 2016-08-01 2019-06-06 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
BR112019007920A2 (pt) * 2016-10-21 2019-10-08 Altor Bioscience Corp moléculas multiméricas à base de il-15
CA3046120A1 (en) * 2017-01-20 2018-07-26 Novartis Ag Combination therapy for the treatment of cancer
SG11202007240QA (en) * 2018-02-02 2020-08-28 Novartis Ag Combination of sting agonist and il-15/il15-ra for the treatment of cancer
JP2021514625A (ja) * 2018-03-01 2021-06-17 グリコトープ ゲーエムベーハー 抗ｍｕｃ１抗体およびｉｌ−１５を含む融合タンパク質構築物

Also Published As

Publication number Publication date
JP2023145622A (ja) 2023-10-11
AU2021215893A1 (en) 2022-08-25
CR20220367A (es) 2022-08-30
CL2023002447A1 (es) 2024-03-15
CA3168469A1 (en) 2021-08-12
UY39062A (es) 2021-09-30
US20210244821A1 (en) 2021-08-12
CO2022010860A2 (es) 2022-08-19
AR121261A1 (es) 2022-05-04
IL295278A (en) 2022-10-01
WO2021156720A1 (en) 2021-08-12
MX2022009611A (es) 2022-11-07
JP2022522566A (ja) 2022-04-20
KR20220137651A (ko) 2022-10-12
CN115023436A (zh) 2022-09-06
DOP2022000156A (es) 2022-10-16
PE20221509A1 (es) 2022-10-04
BR112022014493A2 (pt) 2022-09-20
TW202142558A (zh) 2021-11-16
ECSP22060286A (es) 2022-09-30
JOP20220174A1 (ar) 2023-01-30
EP4100425A1 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
CL2022002094A1 (es) Célula cho que expresa heterodímeros il-15
PE20191150A1 (es) Receptores de celulas t con apareamiento mejorado
TWD193105S (zh) 鞋面
TWD195269S (zh) 鞋面
TWD188400S (zh) 鞋面
CL2017002123A1 (es) Heterociclos biciclicos como inhibidores de fgnr
UY35417A (es) Anticuerpos dirigidos contra il-33 y sus usos.
BR112016018537A2 (pt) copolímero de etileno/a-olefina/polieno não conjugado e processo de produção e uso destes.
CR11195A (es) Polipeptidos, dominios variables de anticuerpos y antagonistas
BR112017001550A2 (pt) enxerto de tecido
CL2022002540A1 (es) Nuevos compuestos útiles para el tratamiento y/o prevención de una enfermedad, trastorno o afección asociada con la angiotensina
NZ729008A (en) Plant inoculation method
UY38243A (es) Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos
MX2020003668A (es) Tratamiento de la enfermedad mediada por cml.
BR112018011582A2 (pt) pré-forma para um aparelho de usinagem cad/cam, processo para fabricar a pré-forma, fibra compósita de núcleo de incrustação e uso da pré-forma
EA201592115A1 (ru) Высокопрочный канат и способ его получения
UY35673A (es) Procedimiento de fabricación de fibras sintéticas estructurales para hormigones y morteros, y fibra sintética obtenida
RO133069A3 (ro) Sistem şi dispozitiv de iluminat cu diode electroluminiscente
AR097709A1 (es) Fibras de poliolefina de pequeño diámetro
RU2013137672A (ru) ШТАММ МИКРОВОДОРОСЛИ Chlorella vulgaris, ПРЕДНАЗНАЧЕННЫЙ ДЛЯ ОЧИСТКИ СТОЧНЫХ ВОД СЕЛЬСКОХОЗЯЙСТВЕННЫХ И СПИРТОВЫХ ПРОИЗВОДСТВ
TR201902150U5 (tr) Plastik Boru Üretim Hattında Kullanılan Vakum Havuzu
AR116175A1 (es) Un dispositivo de disposición y orientación radicular de plantas
Giunashvili Studia Litteraria Universitatis Iagellonicae Cracoviensis, Volume 14 (2019), Special Issue. A Volume in Honour of Professor Anna Krasnowolska. Editor-in-Chief: Celina Juda
TR201818529A2 (tr) Nano hi̇droli̇k ki̇reç i̇çeren hazir enjeksi̇yon malzemesi̇ üreti̇m yöntemi̇
PL431696A1 (pl) Ozdoby na znicze